S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.22%)
Log in
NASDAQ:EPIX

ESSA Pharma Competitors

$26.81
-0.37 (-1.36 %)
(As of 03/4/2021 04:30 PM ET)
Add
Compare
Today's Range
$25.20
Now: $26.81
$28.50
50-Day Range
$14.11
MA: $21.29
$28.65
52-Week Range
$3.00
Now: $26.81
$32.69
Volume352,941 shs
Average Volume450,825 shs
Market Capitalization$859.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96

Competitors

ESSA Pharma (NASDAQ:EPIX) Vs. LEGN, KRTX, MOR, AGIO, FGEN, and ALXO

Should you be buying EPIX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ESSA Pharma, including Legend Biotech (LEGN), Karuna Therapeutics (KRTX), MorphoSys (MOR), Agios Pharmaceuticals (AGIO), FibroGen (FGEN), and ALX Oncology (ALXO).

Legend Biotech (NASDAQ:LEGN) and ESSA Pharma (NASDAQ:EPIX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.

Earnings & Valuation

This table compares Legend Biotech and ESSA Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$64.39 million48.28$-132,970,000.00N/AN/A
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-25.78

ESSA Pharma has lower revenue, but higher earnings than Legend Biotech.

Analyst Recommendations

This is a summary of recent recommendations for Legend Biotech and ESSA Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Legend Biotech00303.00
ESSA Pharma00503.00

Legend Biotech currently has a consensus price target of $50.6667, suggesting a potential upside of 115.69%. ESSA Pharma has a consensus price target of $28.80, suggesting a potential upside of 6.82%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than ESSA Pharma.

Profitability

This table compares Legend Biotech and ESSA Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Legend Biotech-543.73%-205.60%-43.03%
ESSA PharmaN/A-46.31%-45.08%

Insider & Institutional Ownership

18.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 63.4% of ESSA Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ESSA Pharma beats Legend Biotech on 5 of the 8 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares ESSA Pharma and Karuna Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-25.78
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-32.00

Karuna Therapeutics is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ESSA Pharma has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for ESSA Pharma and Karuna Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ESSA Pharma00503.00
Karuna Therapeutics001103.00

ESSA Pharma currently has a consensus target price of $28.80, suggesting a potential upside of 6.82%. Karuna Therapeutics has a consensus target price of $141.70, suggesting a potential upside of 20.22%. Given Karuna Therapeutics' higher possible upside, analysts clearly believe Karuna Therapeutics is more favorable than ESSA Pharma.

Profitability

This table compares ESSA Pharma and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ESSA PharmaN/A-46.31%-45.08%
Karuna TherapeuticsN/A-13.91%-13.72%

Insider & Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are owned by institutional investors. 18.1% of Karuna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Karuna Therapeutics beats ESSA Pharma on 7 of the 10 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Volatility & Risk

ESSA Pharma has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.

Insider & Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 3.1% of MorphoSys shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ESSA Pharma and MorphoSys' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-25.78
MorphoSys$80.43 million39.42$-115,380,000.00($0.91)-26.48

ESSA Pharma has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for ESSA Pharma and MorphoSys, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ESSA Pharma00503.00
MorphoSys05302.38

ESSA Pharma currently has a consensus target price of $28.80, suggesting a potential upside of 6.82%. Given ESSA Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe ESSA Pharma is more favorable than MorphoSys.

Profitability

This table compares ESSA Pharma and MorphoSys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ESSA PharmaN/A-46.31%-45.08%
MorphoSys8.76%4.51%2.25%

ESSA Pharma (NASDAQ:EPIX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Risk and Volatility

ESSA Pharma has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.

Insider and Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are owned by institutional investors. 3.2% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ESSA Pharma and Agios Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-25.78
Agios Pharmaceuticals$117.91 million27.94$-411,470,000.00($6.86)-6.90

ESSA Pharma has higher earnings, but lower revenue than Agios Pharmaceuticals. ESSA Pharma is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ESSA Pharma and Agios Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ESSA Pharma00503.00
Agios Pharmaceuticals03802.73

ESSA Pharma presently has a consensus price target of $28.80, suggesting a potential upside of 6.82%. Agios Pharmaceuticals has a consensus price target of $64.6364, suggesting a potential upside of 37.12%. Given Agios Pharmaceuticals' higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than ESSA Pharma.

Profitability

This table compares ESSA Pharma and Agios Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ESSA PharmaN/A-46.31%-45.08%
Agios Pharmaceuticals-170.65%-57.63%-37.15%

Summary

Agios Pharmaceuticals beats ESSA Pharma on 7 of the 13 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and FibroGen (NASDAQ:FGEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Risk and Volatility

ESSA Pharma has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Insider and Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 75.1% of FibroGen shares are owned by institutional investors. 3.4% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ESSA Pharma and FibroGen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-25.78
FibroGen$256.58 million12.04$-76,970,000.00($0.89)-37.90

ESSA Pharma has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ESSA Pharma and FibroGen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ESSA Pharma00503.00
FibroGen13402.38

ESSA Pharma presently has a consensus price target of $28.80, suggesting a potential upside of 6.82%. FibroGen has a consensus price target of $53.5714, suggesting a potential upside of 58.73%. Given FibroGen's higher possible upside, analysts plainly believe FibroGen is more favorable than ESSA Pharma.

Profitability

This table compares ESSA Pharma and FibroGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ESSA PharmaN/A-46.31%-45.08%
FibroGen-191.78%-48.19%-27.72%

Summary

FibroGen beats ESSA Pharma on 7 of the 13 factors compared between the two stocks.

ESSA Pharma (NASDAQ:EPIX) and ALX Oncology (NASDAQ:ALXO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Insider and Institutional Ownership

63.4% of ESSA Pharma shares are owned by institutional investors. Comparatively, 73.5% of ALX Oncology shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ESSA Pharma and ALX Oncology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-25.78
ALX OncologyN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for ESSA Pharma and ALX Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ESSA Pharma00503.00
ALX Oncology00603.00

ESSA Pharma presently has a consensus price target of $28.80, suggesting a potential upside of 6.82%. ALX Oncology has a consensus price target of $89.60, suggesting a potential upside of 9.94%. Given ALX Oncology's higher possible upside, analysts plainly believe ALX Oncology is more favorable than ESSA Pharma.

Profitability

This table compares ESSA Pharma and ALX Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ESSA PharmaN/A-46.31%-45.08%
ALX OncologyN/AN/AN/A

Summary

ALX Oncology beats ESSA Pharma on 5 of the 5 factors compared between the two stocks.


ESSA Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LEGN
Legend Biotech
1.2$23.55-9.5%$3.40 billion$64.39 million0.00Increase in Short Interest
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$117.76-3.3%$3.29 billionN/A-58.59Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
MorphoSys logo
MOR
MorphoSys
0.4$24.10-2.7%$3.26 billion$80.43 million114.77News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$47.33-2.6%$3.21 billion$117.91 million-9.60Analyst Downgrade
Analyst Revision
FibroGen logo
FGEN
FibroGen
1.6$33.73-1.8%$3.13 billion$256.58 million-12.92Earnings Announcement
Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$81.22-3.3%$3.11 billionN/A0.00Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$67.22-3.2%$3.01 billion$421.03 million23.67Analyst Report
News Coverage
Alkermes logo
ALKS
Alkermes
1.4$18.21-2.4%$2.97 billion$1.17 billion-39.59Analyst Revision
Viela Bio logo
VIE
Viela Bio
0.8$52.96-0.0%$2.91 billion$50 million-7.54Earnings Announcement
Decrease in Short Interest
Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$4.19-3.1%$2.81 billion$901.90 million-23.28
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$23.85-2.3%$2.80 billion$306.49 million26.80
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.35-3.0%$2.78 billion$182.24 million-9.00Earnings Announcement
Analyst Report
Analyst Revision
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.8$50.06-5.7%$2.77 billionN/A-27.51Earnings Announcement
Analyst Report
Analyst Revision
Gap Up
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$70.70-1.1%$2.74 billion$644.77 million-10.09Increase in Short Interest
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$33.27-1.0%$2.67 billion$60,000.00-10.33
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$66.21-6.0%$2.62 billionN/A-24.61Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
PRLD
Prelude Therapeutics
1.0$55.80-6.7%$2.60 billionN/A0.00Upcoming Earnings
Xencor logo
XNCR
Xencor
1.0$44.19-1.3%$2.59 billion$156.70 million-31.56Analyst Upgrade
Insider Selling
Analyst Revision
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$42.96-3.1%$2.55 billion$25 million-8.59
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.34-4.9%$2.51 billion$2.11 million-8.73Analyst Revision
IGMS
IGM Biosciences
2.0$74.77-8.7%$2.50 billionN/A-31.82Insider Selling
News Coverage
Gap Up
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$141.71-4.3%$2.46 billion$120.28 million-143.14Decrease in Short Interest
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.39-3.5%$2.45 billion$15 million-17.48Analyst Report
Analyst Revision
News Coverage
MORF
Morphic
1.1$69.09-3.5%$2.23 billion$16.98 million-44.29Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
Gap Up
Generation Bio logo
GBIO
Generation Bio
1.6$34.63-15.3%$2.22 billionN/A0.00Upcoming Earnings
Analyst Report
Amarin logo
AMRN
Amarin
1.6$5.72-1.9%$2.22 billion$429.76 million-114.38
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$27.06-7.2%$2.21 billion$23.90 million-16.81Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Cryoport logo
CYRX
Cryoport
1.7$52.09-5.6%$2.18 billion$33.94 million-89.81Earnings Announcement
Analyst Upgrade
Analyst Revision
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$42.45-0.3%$2.11 billion$963.01 million13.18
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.3$59.64-1.7%$2.08 billionN/A0.00
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$21.00-8.7%$2.07 billionN/A-7.47
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.0$56.89-4.2%$1.98 billionN/A-31.61
Kura Oncology logo
KURA
Kura Oncology
1.6$31.02-3.7%$1.98 billionN/A-19.03Analyst Report
Analyst Revision
Gap Up
HRMY
Harmony Biosciences
1.4$33.02-5.0%$1.97 billionN/A0.00Analyst Downgrade
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$27.08-4.7%$1.96 billion$103.54 million-20.36Insider Selling
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$25.71-0.4%$1.84 billion$410,000.00-5.59Analyst Report
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$61.49-0.2%$1.82 billion$970,000.000.00Upcoming Earnings
Analyst Report
Increase in Short Interest
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$112.08-0.0%$1.80 billionN/A-10.12Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$43.55-0.2%$1.77 billionN/A0.00Upcoming Earnings
ADCT
ADC Therapeutics
1.6$23.76-7.0%$1.75 billion$2.34 million-10.07News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.3$40.50-1.9%$1.72 billionN/A0.00Upcoming Earnings
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
2.0$13.41-7.2%$1.71 billion$320,000.00-9.12Analyst Revision
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.36-3.9%$1.69 billion$82.27 million-20.39
ORGO
Organogenesis
1.0$14.59-5.7%$1.66 billion$260.98 million-243.17Gap Up
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$39.61-15.1%$1.64 billionN/A0.00Upcoming Earnings
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$30.69-5.7%$1.62 billionN/A-3.33
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$18.11-2.5%$1.61 billion$34.51 million-15.48Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$9.99-0.2%$1.60 billion$428.41 million14.48Insider Buying
Kronos Bio logo
KRON
Kronos Bio
1.8$29.32-2.9%$1.59 billionN/A0.00Upcoming Earnings
News Coverage
Endo International logo
ENDP
Endo International
1.3$6.89-0.6%$1.58 billion$2.91 billion-10.13Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.